The dsm-firmenich|Novozymes Feed Enzymes Alliance today announces the commercial release of its breakthrough second-generation protease, ProAct 360™.
ProAct 360™ sets a new market standard in protease technology for poultry on three key fronts: feed efficiency, affordability, and sustainability. This innovative feed solution delivers more consistent improvements in growth performance, along with improved matrix values for key amino acids and faster action. As its name suggests, ProAct 360™ reflects a 360° understanding of the needs of poultry producers, and also of the challenges that poultry production can face with regard to environmental footprint.
ProAct 360™ helps feed producers to be more flexible in their selection and use of raw materials, reducing the industry’s reliance on soy and other major crops while at the same time helping to cut feed costs. It also significantly enhances the digestibility of protein, ensuring greater retention of nitrogen in the metabolism and therefore lower nitrogen emissions to the environment.
With its enhanced potency, ProAct 360™ offers improved returns on investment and its value proposition goes beyond the product itself. It includes a unique set of value-adding end-to-end digital services, ranging from raw material analysis to a sustainability calculator, that enable deeper insights and more informed decision-making.
Christie Chavis, Vice President at dsm-firmenich Animal Nutrition and Health, observes: “ProAct 360™ is our latest breakthrough technology in sustainability-driven innovation. Improving sustainability while reducing feed costs and supporting animal welfare is the key requirement for the animal protein industry today. The launch of ProAct 360™ is an important proof point of our strategic initiative We Make it Possible, which is designed to deliver solutions that enable the transition to fully sustainable animal protein production worldwide.”
Robert Vergo, Account Director, Global Strategic Accounts at Novozymes, comments: “ProAct 360™ is the latest of many ground-breaking innovations from the dsm-firmenich|Novozymes Feed Enzymes Alliance. Selected via a rigorous screening process involving more than 500 protease candidates, it is a novel and robust protease product tailored to the needs of today’s feed industry. ProAct 360™ has been perfected for progress, reflecting a complete perspective on our customers’ commercial sustainability plans and targets. With the launch of this second-generation protease, we are inviting our customers to join us on the journey toward a genuinely sustainable animal production industry.”
The dsm-firmenich|Novozymes Alliance pioneered feed protease technology 10 years ago with the launch of its first-generation ProAct, which became the market standard for improving amino acid digestibility in animal feed. The need for protease-based solutions is greater than ever today, with animal protein producers facing a volatile market characterized by high protein meal prices and a slow recovery from the effects of the COVID-19 pandemic.
With the launch of ProAct 360™, the dsm-firmenich|Novozymes Alliance intends to make protease technology broadly available to poultry customers, to support the development of a more sustainable global animal production industry, once more delivering on its We Make it Possible promise.
ProAct 360™ will initially be launched in the markets of Latin America, with a roll-out to the other regions of the world to follow in the medium term. Future swine applications are being studied.
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we find biological answers to preserve the planet’s resources and help build better lives. As the world’s largest provider of enzyme and microbial technologies, our bio-innovation enables increased health and nutritional benefits, higher agricultural yields, improved washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com
07 June 2021
+31 6 1038 1639
We detected that you are visitng this page from United States. Therefore we are redirecting you to the localized version.